Replies to post #95631 on Amarantus Bioscience Holdings Inc (AMBS)

[blackhawks]

Risk:

I am glad you see the true colors with the Financing arrangements here. And so does JP....I think Gerald has done very well for himself and the company on so many fronts....but a huge miss on the financing deals.

Here is the flaw in all of the critiques of Gerald's financial acumen. He could have an MBA from Wharton with a dissertation in Biotech Financial Deals and it simply would not matter until the AMBS science reached a 'critical mass' consisting of successful clinical trials with potentially competitively advantaged products,

Substitute any of AMBS' current product pipeline where you see underlines below, and ask yourself honestly if any AMBS product currently belongs there.

And test my proposition with this question. If a deal for any of AMBS product were announced on Monday next, would it be because Gerald or his financial deals staff 'all-star' suddenly became competent in ways they formerly were not, or would it more likely be because newly persuasive scientific data became available?

I'm not saying that Gerald has not turned away low-ball offers, I simply don't know. I am suggesting that AMBS is not as scientifically strong, at this point, as are companies that AMBS is being unfavorably compared with in deal making.

The one below is so clearly an apples to oranges comparison with AMBS, product data wise, it begs the question of why it was even posted.


http://ih.advfn.com/p.php?pid=nmona&article=61169657

Make no mistake about it -- Nuvilex is now a competitor to biopharmaceutical giants Eli Lilly and Celgene. With the company's advanced pancreatic cancer treatment that combines the Cell-in-a-Box technology with ifosfamide already providing better results than both Eli Lilly's gemcitabine alone and Celgene's Abraxane-gemcitabine combination in two earlier independent Phase II trials, the future for Nuvilex and its investors could get very interesting, very quickly.

The biotechnology sector is a cash intensive arena, and unfortunately to bring world class therapies to bear, it requires a great deal of money. Many companies with great treatments throw in the towel because they can never land that funding. However, the team at Nuvilex worked diligently to convince someone, anyone that Cell-in-a-Box can revolutionize the industry. It's a process every small firm must endure, and many fail at it.

Nuvilex had the data on their side which probably made convincing Lincoln Park Capital a little bit easier. After all, in pancreatic cancer alone, Nuvilex has the numbers to upset Celgene and Eli Lilly, two companies that have a "gold standard" treatment for advanced inoperable cancer. It's a treatment that has earned Eli Lilly billions of dollars.